Formation strategies, mechanism of intracellular delivery and potential clinical applications of pH-sensitive liposomes  by Liu, Xin & Huang, Guihua
ww.sciencedirect.com
a s i a n j o u rn a l o f p h a rm a c e u t i c a l s c i e n c e s 8 ( 2 0 1 3 ) 3 1 9e3 2 8Available online at wScienceDirect
journal homepage: http : / /ees.e lsevier .com/ajps/defaul t .aspReview
Formation strategies, mechanism of intracellular delivery and
potential clinical applications of pH-sensitive liposomesXin Liu, Guihua Huang*
School of Pharmaceutical Science, Shandong University, No. 44 Wenhua Xi Road, Ji’nan 250012, Chinaa r t i c l e i n f o
Article history:
Received 18 October 2013
Received in revised form
5 November 2013
Accepted 11 November 2013
Keywords:
pH-sensitive liposomes
Triggered release
Drug delivery
Gene therapy
Vaccine
Magnetic resonance imaging (MRI)* Corresponding author. Tel.: þ86 0531 883820
E-mail address: hgh2003@126.com (G. Huang
Peer review under responsibility of Shenyan
Production and hosting by El
1818-0876/$ e see front matter ª 2013 Sheny
http://dx.doi.org/10.1016/j.ajps.2013.11.002a b s t r a c t
pH-sensitive liposomes are designed to specifically triggered release the loaded drugs in
response to the change of pH in the surrounding serum. So pH-sensitive liposomes can
effectively deliver drug or gene fragments into the cytoplasm via the endocytotic pathway.
Furthermore, pH-sensitive liposomes can be successfully used in clinical if they enable the
encapsulated drugs to be targeted to pathological tissues (such as primary tumors, me-
tastases, local ischemia, inflammation and infection) of the body in which pH is less than
the normal physiological value. That’s the reason why a growing amount of literatures
described the development and applications of pH-sensitive liposomes to improve the
therapeutic index of the encapsulated active ingredients. In this review, the commonly
used pH-sensitive molecules for pH-sensitive liposome and the mechanisms of intracel-
lular delivery of pH-sensitive liposomes were addressed. Besides, the potential clinical
applications were fully discussed in detail with an expectation to contribute to the clinical
research of pH-sensitive liposomes.
ª 2013 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. All
rights reserved.1. Introduction
The design and synthesis of hundreds of new drug candidates
with potential activity against a wide range of therapeutic
targets in vitro have resulted from recent advances in
biomedical science, high throughput screening and combi-
natorial chemistry. However, most of the new drugs spread
out in the system with no specific targeting and sometimes
with toxic side effects (e.g., anemia, vomiting, diarrhea,15; fax: þ86 0531 8838254
).
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when they are intravenously administered [1-3]. Furthermore,
they may be detected and absorbed by the reticuloendothelial
system (RES) or mononuclear phagocyte system (MPS) prior to
interacting with cell membranes when they were delivered
into the bloodstream. As a result, only a small fraction of
unaffected substance appears in the cell cytoplasm, which
will further give rise to the failure to fully develop the poten-
tial in clinical.8.
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Fig. 2 e Intracellular delivery by pH-sensitive and plain
liposome.
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great attention to improving drug efficacy and decrease un-
desired side effects by developing new drug delivery systems.
Therefore, establishing a superior delivery system that is able
to encapsulate drug in a biocompatible carrier to deliver suf-
ficient drug specifically to the site of disease may be one so-
lution to those problems mentioned above. As a delivery
system, liposomes have been one of the most common used
andwell-investigated to evade RES detection and achieve high
therapeutic efficiency of a drug at a target site while at the
same time reducing or avoiding toxic side effects [4e6].
Liposomes are typically spherical self-closed structures
composed of curved self-assembled lipid bilayers with a size
vary from 50 to 1000 nm. Since their discovery and recognition
of the structure and basic properties, liposomes have been
interesting for applications in a wide range of areas from
medicine and cosmetics to food technology and ecology, as
they can encapsulate hydrophilic solutes in their interior
aqueous compartment and incorporate hydrophobic sub-
stances into the hydrophobic compartment of the phospho-
lipid bilayer (Fig. 1). This kind of delivery system has the
advantages of targeted [7], long circulation [8], low toxicity [9],
sustained-release [10], no immunogenicity [11] and protecting
the encapsulated drugs from the destructive action of the
external media [12]. Among these advantages, the most
common reason for applying liposomes to drug delivery is
probably the improved pharmacokinetics profile. The pre-
dominance in drug delivery has enabled liposomes to be used
as a therapeutic tool in tumor targeting, gene therapy,
immunomodulation and genetic vaccination. The growing
number of liposomal formulations in the market (e.g., Doxil,
Daunoxome and Myocet, etc.) or currently under clinical
evaluation (e.g., Lipoplatin, liposomal cisplatin under Phase
III clinical trials; Thermodox, liposomal doxorubicin under
Phase Ⅰ clinical trials) provide best proof of their enormous
potential [13].
However, after intravenous administration, the conven-
tional liposomes are still rapidly recognized and uptaken by
the cells of the RES mainly in liver and spleen and removed
from the circulation, which leads to short plasma half-lives
[14]. Therefore their clinical potential has been largely
limited. Besides, liposomes enter cells mainly via the endo-
cytotic pathway and eventually reach the lysosomewithin the
cell. In the lysosome, liposomes and their encapsulated drugs
or gene that cannot escape the endosome are exposed to the
risk of being degraded by lysosomal enzymes (Fig. 2), which
will further significantly reduce the drug efficacy and the level
of gene expression [15].Fig. 1 e Structures of unilamellar liposome.To solve this problem, many stimuli-sensitive liposomes
have been and are being developed that avoid lysosomal
degradation of loaded drugs and release their substance in
one single burst as a result of destabilization of the liposome
membrane caused by certain internal or external stimuli (such
as changes of physiological pH, tissue specific enzymes,
physiological temperature or electrolyte concentration, etc.)
[16,17]. Among these trigger-release liposomes, pH-sensitive
liposomes have been an attractive strategy to avoid lyso-
somal sequestration and degradation, which is a serious
hurdle for intracellular delivery of drugs of low cellular
permeation ability and enzymatic instability.
pH-sensitive liposomes can be prepared by simply adding
pH-sensitive units to the liposome dispersion or by mixing
pH-sensitive lipids and polymers during the preparation of
vesicles [18]. Such liposomes stay intact at physiological pH
but destabilize and acquire fusogenic properties under acidic
conditions (pH7.4 w 5.3) of the target tissue, thus leading to
efficiently release of their aqueous encapsulated contents into
the cytoplasm [19]. Therefore a high local drug level at the
target site is obtained due to their controlled release. Besides,
they are stably internalized by cells mainly via an endocytic
pathway, and they are destabilized at low pH (w5) in the en-
dosome hence the drugs can be easily released into cytoplasm
or actively targeted to lesions [20,21]. So the drugs or gene
fragments that are encapsulated into pH-sensitive liposomes
can effectively escape lysosomal sequestration and degrada-
tion. Therefore drug loaded pH-sensitive liposomes are
believed to increase the efficiency of targeting drugs to desired
cellular sites while effectively protecting them from being
potentially degraded at the lysosomal level (Fig. 2) [22]. That’s
the reason why recent progress and the insight gained from
clinical use of pH-sensitive liposomal formulations are
highlighted.2. pH-sensitive molecules for liposomes
triggering
Various strategies for formulating pH-sensitive liposomes
have been reported and developed in the past decades. pH-
a s i a n j o u rn a l o f p h a rm a c e u t i c a l s c i e n c e s 8 ( 2 0 1 3 ) 3 1 9e3 2 8 321sensitive liposomes mainly depend upon acid-induced
destabilization of the vesicle bilayer structure. So this review
divided pH-sensitive liposomes that are commonly used into
the following four categories based on their components and
the mechanism of triggering pH-sensitivity.
2.1. Combine polymorphic lipids
The typical polymorphic lipid used to prepare pH-sensitive
liposomes is the unsaturated phosphatidylethanolamine
(PE), such as diacetylenic-phosphatidyl-ethanolamine (DAPE),
palmitoyl-oleoyl-phosphatidyl-ethanolamine (POPE) and
dioleoyl-phosphatidyl-ethanolamine (DOPE) [23]. DOPE is
usually combined with mildly acidic amphiphiles that act as
stabilizers at neutral pH, such as oleic acid (OA), cholesteryl
hemisuccinate (CHEMS) (Fig. 3) and palmitoyl homocysteine
(PHC), to formulate pH-sensitive liposomes. Their carboxyl
group was protonated in the acidic environment such as that
found in the lumen of endosomes or lysosome. The three-
dimensional volume of the hydrophilic side got small and
lost its remedy to the phospholipid accordingly, which will
result to membrane destabilization of pH-sensitive liposomes
[24]. Then the encapsulated bioactivemolecules were released
from pH-sensitive liposomes into the cytoplasm.
2.2. Contain “cage” lipid derivatives
Most of this kind of liposome contains the derivatives of PE or
annular lipid compositions with alkyl ether [25], such as N-
citraconyl-dioleoyl-phosphatidyl- ethanolamine (C-DOPE)
and N-citraconyl-dioleoyl-phosphatidylserine (C-DOPS). Li-
posomes that contain such compositions can reversibly
exhibit the ability to form non-bilayer phase simply with the
drug permeable membranes or with the fusion competentFig. 3 e Chemical structures of the commonly used lipids
for the construction of pH-sensitive liposome: A. PE, B.
DOPE, C. OA, D. CHEMS.included. The process mentioned above was performed by
reversibly covalent modifying of a nucleophilic functionality
on the head group of the lipid or cleaving the alkyl group of the
liposome in the blood circulation to expose the long-chain of
fatty acids that can undermine the stability of the biofilm [26]
and thus increased permeability to entrapped drugs. So Daryl
and David [27] indicate that the pH-sensitive liposomes
that contain N-acyl-phosphatidylethanolamine can not only
release their encapsulated contents in the environment of
low pH values, but also promote the fusion with the cell
membrane. Finally, poly(ethylene-glycol)-N-distearolyphos-
phatidyl-ethanolamine (PEG-DSPE), a new synthesized con-
jugate with a liable linkage, is another potentially very
important “caged” lipid. The addition of PEG to the surface of
liposomes reduced the RES uptake and simultaneously pro-
longed the duration of liposomes in the circulatory system
[28].
2.3. Composed of synthetic fusogenic peptides/proteins
By inserting the pH-sensitive peptide/proteins, such as GALA,
the N-terminus of hemaglutinin (INF peptides from influenza)
or the listeriolysin O into the phospholipid double-fusion
peptide or protein, thus a kind of novel pH-sensitive lipo-
somes is developed. The peptide or protein is inactive when
such liposomes are in the neutral pH environment. While in
the acidic environment, the conformation of the fusion pep-
tide or protein changed, which will promote the fusion be-
tween liposomalmembrane and cell membrane [29]. Then the
pH-sensitive liposomes release the encapsulated contents
eventually.Withmembrane destabilization inducing by either
full proteins or peptides, liposomal or lipid-based delivery
systems can be triggered in response to pH. For example,
GALA is a 30 amino acid synthetic peptidewith a repeat unit of
glutamic acid-alanine-leucine-alanine (EALA) [30]. EALA un-
dergoes a pH-dependent conformational change from random
coil at pH 7.5 to an amphipathic helix at pH 5 and induces
leakage of contents from large unilamellar PC vesicles when in
an a-helical conformation acids. Leakage of water-soluble
fluorescent contentsmarkers was shown to be rapid below pH
6 and maximal around pH 5, while being relatively slow at
neutral pH [31]. Provoda et al [32] encapsulated Gelonin (a type
I plant toxin) inside pH-sensitive liposomes with listeriolysin
O, the pore-forming protein that mediates escape of the
intracellular pathogen Listeria monocytogenes from the en-
dosome into the cytosol. By direct intratumor injection into
subcutaneous solid tumors of B16 melanoma in a mouse
model, the results showed that this kind of pH-sensitive li-
posomes can improve the efficiency in curtailing tumor
growth rates.
2.4. Constructed with pH-sensitive polymers
In recent years, growing scientific attention in the formulation
of liposomal preparations has resulted from synthetic poly-
mers. These polymers reported for the design of pH-sensitive
liposomes are based on poly (alkyl acrylic acid)s, succinylated
PEG, and N-isopropylacrylamide (NIPAM) copolymers [33].
Polymers exhibited one interesting feature that they can be
tailored to participate actively in the release of drugs upon an
Fig. 4 e Possible clinical applications of pH-sensitive liposome.
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with the lipid bilayer, which promotes the fusion between li-
posomes and endsomal membrane [34]. Roux et al found that
NIPAM and its derivatives can endow the liposomes with
Specific pH-sensitivity [35]. Such polymers can be attached to
the surface of drug/DNA-loaded liposomes, which contributes
to endosomal destabilization and cytoplasmic escape. Zignani
et al [36] demonstrated rapid and pH-sensitive release of a
highly water-soluble fluorescent aqueous content marker,
pyranine, from egg phosphatidylcholine liposomes following
incorporation of N-isopropylacrylamide (NIPA) copolymers in
liposomal membranes. Yuba et al [37] modified of liposomes
with hyperbranched poly (glycidol) (HPG) derivative, which is
used as a new type of pH-sensitive polymer. Results demon-
strated that the backbone structure of pH-sensitive polymers
had great impact on their pH-sensitivity and interaction with
liposomal and cellular membranes.
All four classes offer unique advantages and disadvantages
that may vary in potential depending on the desired applica-
tion purpose and methods.3. Mechanisms of intracellular delivery
mediated by pH-sensitive liposomes
Generally, as is discussed in the Section 2, the commonly used
pH-sensitive lipid to design pH-sensitive liposomes is PE and
its derivatives, such as DOPE. PE contains a minimally hy-
drated and small head group that occupies a lower volume as
compared with the respective hydrocarbon chains, exhibiting
a cone shape, which hinders the formation of a lamellar
phase. Besides, PE can effectively assemble into non-bilayer
structures in an inverted hexagonal phase when dispersed in
pure form. The PE bilayers can also be stabilized in the
lamellar phase by the additions of some lipid constituents or
co-surfactant that contains a carboxylic acid group [38]. By
incorporating these acid-titratable charged amphiphilicmolecules, the intermolecular interaction of the PE head-
groups can be reduced by the electrostatic repulsion of
charged groups, thus the pH-sensitive liposomes that are
stable at physiological pH and temperature can be
constructed.
It is reported that pH-sensitive liposomes that can suc-
cessfully circumvent the endosome are internalized by cells
more effectively than non-pH-sensitive liposomes [39]. This
phenomenon can be explained by their high affinity to adhere
to cellmembranes due to the poor hydration head group of PE-
containing liposomes resulting in aggregation. Following
receptor-mediated endocytosis, liposomes will be retained in
the early endosomes (internal pH 6.5), which will mature into
late endosomes (internal pH 5.5 w 6.5) independents of the
internalization process. So the compounds that cannot escape
the endosome (internal pH 4.5 w 6.5) and accordingly end up
in the lysosome (internal pH 5.0 or lower) are exposed to the
risk of being destructed by the lysosomal enzymes. This pro-
cess will result in a limited delivery of therapeutic agents to
the intracellular targets. However, as the pH decreases, the
carboxylic group of the amphiphiles reduces their stabilizing
effect, thus pH-sensitive liposomes can convert from con-
ventional bilayer sheet of the lipoidal membrane to inverted
hexagonal phase. The pH-sensitive liposomes composed of PE
and co-surfactant were destabilized as a result of the acidifi-
cation of either in endosomal compartments or pathological
tissues, such as tumor interstitial fluid or inflamed tissue. And
the loaded drug can be released into the cytosol due to the
subsequent destabilization of the endosomal membrane. Be-
sides, the encapsulated compounds can be released directly
into the cytoplasm due to the fusion between pH-sensitive
liposomes and the endosomal membrane (Fig. 2). This func-
tion of pH-sensitive liposomes enabled the loaded bioactive
materials to evade the degradation at the lysosomal level and
therefore increase entry to the cytosolic or nuclear targets [40].
The concrete mechanisms for different kind of pH-sensitive
liposomes may vary depending on the phosphatidylcholine
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in detail any more.4. Applications of the pH-sensitive
liposomes
After being endocytosed in the intact form, pH-sensitive li-
posomes fuse with the endovacuolar membrane on the con-
dition of lower pH value inside the endosome and destabilize
it, thus releasing their content into the cytoplasm. So pH-
sensitive liposomes can be appropriately designed to release
their encapsulated contents, especially the biological macro-
molecules, such as drugs [41], enzymes [42], antibodies [43]
and antisense oligonucleotide (ODN) [44], plasmids [45], pro-
teins and peptides [46], into cytoplasm before reaching the
lysosome to ensure the activity of drugs. Besides, inflamma-
tion, infection, some tumors and local ischemia all will lead to
abnormal acidification of the pathological tissues, so pH-
sensitive liposome in the pH range of 6.5 ～ 7.4, as a delivery
carrier, has great clinical value. That’s why different applica-
tions of pH-sensitive liposomes were envisaged, including for
the transport and specific delivery of potent drugs (for cancer,
pulmonary and infectious diseases), vaccination (as immu-
nological adjuvants), imaging (carrying contrasting agents)
and as well as nucleic acids which is aiming at gene therapy
applications (Fig. 4) [47].
4.1. Drug delivery
It is reported that pH-sensitive liposomes are stable at phys-
iological pH (pH 7.4) but undergo destabilization, and acquire
fusogenic properties under acidic conditions, thus leading to
the release of their aqueous contents. Therefore, in theory,
pH-sensitive liposomes can prolong the circulation time and
improve the efficiency of drug delivery. In practical, pH-
sensitive liposomes have been reported to have possible
clinical implications for delivering drugs to target sites such as
primary tumor and inflammation sites where the pH could be
less than physiological.
4.1.1. Anti-tumor therapy
The systemic chemotherapy is almost impossible to achieve
therapeutic levels of a drug at the solid tumorwithout injuring
the healthy organs and tissues [48]. In addition, several
drawbacks, such as low bioavailability of the chemotoxin, low
drug concentrations at the tumor site, lack of specificity and
drug-resistant also provide obstacle to its clinical applications.
Although the nanocarriers less than 200 nm are able to be
passively targeted to tumor tissue due to the enhanced
permeation and retention (EPR) effect [49]. However, one of
the drawbacks of the conventional drug delivery system is the
fast elimination from the blood and capture by the cells of the
RES, primarily in the liver.
It is reported that the extracellular environment of solid
tumors is acidic with a pH ranging from 5.7 to 7.8 compared
with the pH 7.4 of the blood and normal tissue [50]. pH-
sensitive liposomes can be induced to undergo a pH-induced
fusion of liposomal membranes with endosomal membranes
or destabilization of the endosomalmembrane, thus releasingcontents into cytoplasm. Since most liposomes are internal-
ized by endocytosis, pH-sensitive liposomes undergo desta-
bilization at this step and thus prevent degradation at the
lysosomal level, which can promote cytosolic delivery of the
intact contents [51]. In recent years, as a drug carrier, the
research and application of pH-sensitive liposomes in the
treatment of cancer develop rapidly.
At present, DOPEmay be themost commonly used lipid for
pH-sensitive liposomes. In general, PEG served as a stabilizer
of DOPE containing pH-sensitive liposomes for triggered
release of the loaded anti-cancer drugs. Ishida et al prepared
doxorubicin encapsulated pH-sensitive liposomes with the
mixture of DOPE/HSPC/CHEMS/CHOL/mPEG2000-DSPE at a
molar ratio of 4:2:2:2:0.3 and DOPE/HSPC/CHEMS/CHOL at a
molar ratio of 4:2:2:2 in the hydration way [52]. As a result, pH-
sensitive liposomes increased intracellular drug release rates
within acidic compartment, resulting in a further increase in
the therapeutic efficacy of B lymphoma. Besides, the cisplatin
loaded pH-sensitive liposomes with DOPE/CHEMS/DSPE-PEG
were prepared to cure the small cell lung cancer [53].
Compared with free cisplatin, this formulation has a better
stability in blood and its cytotoxicity is significantly enhanced.
Furthermore, it’s effective for the cells that are tolerance to
cisplatin. So the addition of lipids with covalently attached
PEG in liposomes was shown to avoid the rapid identification
and elimination of theMPS,whichmay contribute to fully take
advantage of the superiority of pH-sensitive liposomes.
pH-sensitive liposomemodified withmonoclonal antibody
could be directed to target to the lesions with a low pH envi-
ronment. The therapeutic efficacy of the anti-cancer drug
entrapped in pH-sensitive liposomes can be improved by the
monoclonal antibody that can direct the pH-sensitive lipo-
somes to the cell surface receptors. Kim et al developed gem-
citabine pH-sensitive liposome (DOPE and CHEMS) with
epidermal growth factor receptor (EGFR) antibody attached
and used A549 cells and BALB/c-nu/nu mouse tumor model
for testing. The results showed that treatment of pH-sensitive
immunoliposomes encapsulating gemcitabine resulted in an
increased apoptosis of tumor cells, leading to tumor growth
inhibition [54]. Simard and Leroux formulated pH-sensitive
immunoliposomes by including a terminally alkylated copol-
ymer of NIPAM in the liposome bilayer and by coupling the
anti-CD33 monoclonal antibody to target leukemic cells.
Finally, the pH-sensitive ILs-CD33 formulation exhibited the
highest cytotoxicity against HL-60 cells [55].
Last but not the least, nucleic acid, plasmid DNA or anti-
sense oligonucleotides mediated by pH-sensitive liposome
can be delivered in the treatment of cancer, as well. The
detailed significance of pH-sensitive liposomes will be dis-
cussed in the section of gene therapy.
4.1.2. Anti-infection therapy
Intracellular infection by bacterial is difficult to manage clin-
ically and is often refractory to conventional chemothera-
peutic treatment strategies due to poor penetration of drug
into cells [56]. As one of the drug carriers mentioned above,
liposomes have achieved their greatest success against
facultative and obligate intracellular pathogens in the treat-
ment of infectious diseases, most notably those with a ten-
dency to infect the MPS. Furthermore, liposomes have shown
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cellular bacteria [57]. In case the infectious focus is located
outside the MPS, conventional liposomes are of limited value.
Therefore, research has been aimed at decreasing the MPS
uptake of liposomes and consequently increasing their cir-
culation time and targeted distribution.
pH-sensitive liposomes can be triggered to release their
contents and fusewith the biomembrane in response to acidic
environment of the infected and inflamed tissues [58]. So the
dissociation of the drug frompH-sensitive liposomes and their
rapid accumulation in the target organs (the liver and spleen)
makes pH-sensitive liposomes an ideal candidate for in vivo
evaluation in an antifungal as well as antibacterial efficacy
model. Lutwyche et al [59] encapsulated gentamicin into pH-
sensitive liposomes composed of DOPE-N-succinyl-DOPE
and DOPE-N-glutaryl-DOPE (70:30; mol:mol) to treat with
murine macrophage-like J774A.1 cells those were infected
with bacteria. As a result, gentamicin encapsulated in lipid
vesicle that undergo pH-dependent lipid mixing and fusion
confered to this membrane-impermeative antibiotic a signif-
icant improvement in therapeutic activity against intracel-
lular bacterial infections. Nasti et al [60] evaluated the efficacy
of pH-sensitive liposomes of nystatin against Cryptococcus
neoformans infection in a murine model. As a result, pH-
sensitive liposomes of nystatin showed better efficacy
compared with its free or egg-PC liposome form against C.
neoformans infection in BALB/c mice. So the enhanced anti-
cryptococcal efficacy of the pH-sensitive nystatin liposomes
can be attributed to the pH-dependent release of the drug in
the low pH environment of lysosomes. Nicolosi et al [61] have
exploited the fusogenic properties of DOPE/DPPC/CHEMS
unilamellar vesicles with the purpose of releasing the antibi-
otic not inside cells but specifically in the narrow area of
periplasmic space of Gram-negative bacteria. As a result, the
outer membrane barrier can be bypassed and antibiotic can
operate its molecular activity at the level of the cell wall. The
enhanced efficacy observed for encapsulated antibiotics in
pH-sensitive liposomes may due to targeted delivery of lipid
carriers to the infected area.
4.2. Gene therapy
Somatic gene therapy has emerged as a new approach for the
treatment of a variety of genetic and acquired diseases [62].
The key to success for any gene therapy strategy is to design a
vector that is able to serve as a safe and efficient gene delivery
vehicle. At present, the common carrier for the study and
clinical application of gene therapy includes viral vector and
non-viral vector. The viral vector has the natural ability to
infect cells efficiently, but there is a potential risk of gener-
ating an infectious, replication-competent virus during the
production or use of viral vectors for gene transfection [63].
While the non-viral vector has no immunogenicity and it is
easily prepared, so it has higher safety in vivo [64].
Liposomes based gene vector has been promoted as a
means of achieving the transfection efficiency of viral vector
without the associated risks. In recent years, with the advent
of cationic liposome [65] and active targeting technology [66],
liposome technology has been widely applied in the transfer
of antisense ODNs for its virtues of high transfectionefficiency, protection for the entrapped and potential of
chemical modification. Besides, they are noninfectious, non-
immunogenic and simple and easy to produce in large scale
[67].
However, non-viral vector, like cationic lipids/liposomes,
also showed certain drawbacks, such as nonspecificity and
cytotoxic reactions [68]. Besides, the efficiencies of gene
transfection meditated by conventional liposomes were
accordingly low. But pH-sensitive liposomes can release the
loaded gene expression system in the cytoplasm before
entering the lysosome by fusion with the biofilm due to the
lipid bilayers of the basic structure of their biofilm. That’s why
pH-sensitive liposomes can transfect gene into cytoplasm
more efficiently and avoids lysosomal degradation to some
extent [69]. So the pH-sensitive liposomes may be a promising
non-viral vector for gene therapy.
Fattal Yuba et al [70] transfected of a murine DC2.4 cells
with pH-sensitive fusogenic liposomes that comprise poly-
mers based on poly (glycidol) with carboxyl group. The results
indicated these complexes with pH-Sensitive fusogenic lipo-
somes exhibited higher transfection activity toward DC2.4
cells than some commercial reagents and hence may be use-
ful as a gene vector for DCs. However, the transfection effi-
ciency of gene delivery directly mediated by pH-sensitive
liposomes was less than the cationic liposomes owning to the
negative charge. So the pH-sensitive cationic liposomes are
expected to be an excellent gene carrier. Rosa et al [71] pre-
condensed plasmid DNA with an arginine-based cationic
surfactant, arginine-N-lauroyl amide dihydrochloride (ALA),
which was incorporated the blood protein transferrin (Tf) into
two cationic liposomal formulations. One composed of a
mixture of dioleoyl trimethylammonio propane and choles-
terol (DOTAP:Chol) and the other pH-sensitive formulation
constituted of DOTAP, Chol, DOPE and CHEMS. The results
demonstrated complexes based on the pH-sensitive liposomal
formulations present better transfection profiles.
Although, compared with the non-pH-sensitive immuno-
liposomes, pH-sensitive immunoliposomes havemuch higher
capacity to mediate cytosolic delivery of the encapsulated
therapeutic molecules due to endosomal escape [72]. Their
stability in the presence of plasma proteins and the stability of
obtaining a sustained-release of the therapeutic agent still put
obstacles to their applications in gene therapy. PEG modifi-
cationmay be a very interesting strategy to solve the problems
mentioned above. C-DOPE, a derivative of DOPE that hydro-
lyzes rapidly at pH 5 to yield DOPE, was synthesized by Low
et al and incorporated with DOPE and folate-PEG-DOPE into
liposomes. The resulting pH-sensitive liposomes were stable
at neutral pH and had a higher transfection efficiency
compared with DOPE-cholesterol hemisuccinate based vec-
tors [73].
4.3. Vaccine delivery adjuvant
Since 1974, Allison et al [74] firstly reported that liposomes can
be used as immunological adjuvant, thorough study has been
made on the implications as a vaccine carrier and adjuvant of
liposomes.
From disposition studies of liposome in vivo, it is reported
that large liposomes are efficiently taken up by macrophages
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main immune organs), which contributes to delivery the an-
tigen to antigen-presenting cells or other immune cells.
Furthermore, liposomes have the function of immunological
adjuvants without the side effect of common adjuvant [75]. A
liposomal vaccine against hepatitis A successfully developed
by the Swiss Serum Institute (Bern, Switzerland) provided the
best proof [76].
However, conventional liposomes are endocytosed on
contact with antigen-presenting cells and degraded, coupled
with the entrapped molecules, inside the endosome via
endosome-lysosome pathway. Whereas, pH-sensitive lipo-
somes release liposomal antigen into the cytoplasm after
endocytosis because of their fusion capacity with the endo-
somal membrane at low pH (range from 5.5e6.5 in the early
and late endosome compartment). Then they were trans-
ported to the endoplasmic reticulum where they combined
with class I molecules. So pH-sensitive liposomes can deliver
the encapsulated material more safely and efficiently than
conventional liposomes, which suggests pH-sensitive lipo-
somes may be a superior vaccine delivery adjuvant [77].
pH-sensitive liposomes have been used as a non-viral ad-
juvants with bacterial, viral, protozoan, tumor and other an-
tigens. Vyas et al [78] prepared and characterized the
Carboxyl-terminal 19 kDa fragment of merozoite surface
protein-1 of Plasmodium falciparum (PfMSP-119) encapsulated
pH-sensitive liposomal formulations using oleyl alcohol
(OAlc) in combination with EPC as the membrane destabiliz-
ing components. The results demonstrated pH-sensitive li-
posomes showed excellent immuno-adjuvant action and
enhanced the immunogenicity of a soluble malaria antigen.
So the present study of pH-sensitive liposomes might open
new ways for the feasibility for the development of blood
stage malaria vaccine.
Besides, the presentation of CTL-peptide antigen mediated
by pH-sensitive liposomes occurs in lymph nodes. Lee et al [79]
investigated the antigen delivery route by pH-sensitive lipo-
somes in vivo using fluorescein isothiocyanate (FITC)-conju-
gated H-2Kb cytotoxic T lymphocyte (CTL) epitope as a model
system. The pH-sensitive liposomal formulations showed sig-
nificant effects on the generation and activation of antigen
specific CTLs, indicating that the formulationsmight be used as
a potential peptide adjuvant for priming and boosting against
target antigens. The results suggest that pH-sensitive lipo-
somes, as a strong peptide adjuvant, may be useful for peptide
delivery for the development of therapeutic or prophylactic
vaccines. Furthermore, strongercellular immune responses can
be induced by ovalbumin-loaded pH-sensitive liposomes from
nasal cavities of mice. Yuba et al [80] developed ovalbumin-
encapsulated pH-sensitive liposomes modified with poly (gly-
cidol) derivatives such as succinylated poly (glycidol) and 3-
methylglutarylated poly (glycidol). Such pH-sensitive lipo-
someswereappliedtoDC2.4cells, amurinedendriticcell line, to
investigate the potential of this fumulation as a carrier of anti-
gen proteins for induction of cellular immunity. The results
indicated that the ability of the polymer-modified pH-sensitive
liposomes to activate cellular immunity and the feasibility to
develop efficient vaccines for immunotherapy.
Liposomes have been reported to promote immune re-
sponses to DNA vaccines by facilitating uptake of the plasmidby antigen-presenting cells [81]. Akita et al [82] reported on a
mechanism-based development of a siRNA delivery system
that was optimized for endsomal fusion bymodifying on a lipid
mixture with a pH-dependent fusogenic peptide (GALA).
Furthermore, they applied this system to deliver siRNA to pri-
mary mouse bone marrow-derived dendritic cells. The results
demonstrated that siRNA loaded in this system efficiently
suppressed endogenous gene expression and consequently
enhanced dendritic cell-based cancer vaccine in vivo.
4.4. MRI contrast agents
Magnetic resonance imaging (MRI) technique has become one
of themost important diagnosis tools available in medicine. A
majority of MRI contrast agents in clinical used today are
based on paramagnetic gadolinium complexes that shorten
the relaxation times of free water protons [83]. The contrast
agents in combination with MRI have been effective tools to
get a perspective of inflammation, infarct, tumor, athero-
sclerotic plaques, live stem-cell tracking, brain perfusion and
many other applications [84].
Most of these MRI contrast agents are complexes of gado-
linium (Gd III) as this kind of ion has a highmagnetic moment
and a long electronic relaxation time [85]. They can effectively
pass through the damaged blood-brain barrier [86] and can be
quickly excreted by renal. So their enhancement effect is not
proportional with the concentration. What’s worse, these
contrast agents are all toxic and non-specific, even if their
distribution in the body is far from homogeneous.
As a new contrast agent, liposomes have received growing
attention because of relatively long circulation time in blood,
the ability of development, easily controlled properties and
good pharmacological characteristics. But the contrast agent
of conventional liposomes is easily ruptured and absorbed by
RES, which may reduce the contrast effect. Finally, MRI
contrast agents are presented that react to variables in their
environment, such as magnetism and pH [87]. This concept of
pH-mediated drug release could be investigated in MRI of tu-
mors, infection and local ischemia. Paramagnetic pH-
sensitive liposomes accumulated in the acidic environment
within the pathological tissues could be triggered to structural
rearrangements and thus release the encapsulated contrast
agents into the cytoplasm. So if properly designed, these pH-
sensitive liposomes would exhibit a function as “off-on”
switches and markedly increased contrast effect.
Terreno et al assessed the in vitro potential of several
paramagnetic complexes loaded pH-sensitive liposomes
formulated with the fusogenic phospholipid POPE and the
membrane stabilizer D-a-tocopherol-hemisuccinate, as im-
aging tools for visualizing drug delivery and release processes
by MRI. It was found that the resulted pH-sensitive liposomal
formulation has the potential for visualizing drug delivery and
release processes by in vivo MRI [88].
Besides, the basic properties of pH-sensitive liposomes
loaded with MRI agents were investigated by Lokling et al in a
series of papers. Lokling et al [89] encapsulated a low-molec-
ular-weight Gd-chelate (GdDTPA-BMA) in pH-sensitive lipo-
somes and studied the in vitro relaxometric properties. When
the surrounded pH decreased below physiological value, the
pH-sensitive paramagnetic contrast agent gave a sharp and 6-
a s i a n j o u rn a l o f p h a rma c e u t i c a l s c i e n c e s 8 ( 2 0 1 3 ) 3 1 9e3 2 83267 fold increase in T1 relaxivity due to liposome destabilization
and subsequent leakage of entrapped GdDTPA-BMA.
Then the potential of a pH-sensitive liposomal MRI
contrast agent for low pH in the tumor interstitium was
further investigated. Lokling et al formulated DPPE/DPSG pH-
sensitive liposomal GdDTPA-BMA and investigated its stabil-
ity in blood at physiological pH and pH-sensitivity. The po-
tential of this system for monitoring pH was demonstrated in
an in vitro MRI phantom study. The MRI study indicated that
the DPPE/DPSG system has the potential value as a probe for
mapping pH [90]. The ideal MRI contrast agent will be focused
on the neutral tissue- or organ-targeting materials with high
relaxivity and specificity. So Lokling et al encapsulated gado-
fosveset, a low-molecular-weight Gd-chelate with high affin-
ity for albumin, into pH-sensitive liposomes to study the
biodistribution in healthy rats. The results demonstrated that
this promising system showed in blood a markedly higher
relaxometric response than the corresponding system with
GdDTPA-BMA, due to release of gadofosveset at low pH and
subsequent binding to albumin [91].5. Conclusion and future prospects
It is believed that pH-sensitive liposomes can significantly
increase cytoplasmic delivery of various fluorescent markers
with various molecular sizes, ribozymes, enzymes, cytotoxic
agents, proteins, RNA, and DNA to cells with considerable
efficiency. However, so far, none of this kind of preparations is
used in clinical due to their drawbacks. Because, a clinically
viable pH-sensitive liposomal formulation requires several
essential properties including efficient pH-triggered release,
serum stability, and enough long circulation time in vivo.
Additionally, after being injected into the body, pH-sensitive
liposomes still can be recognized by the opsonin in the
plasma and phagocytized by RES to some extent, which is an
important limitation to the in vivo use and the main barrier of
the delivery of drugs and gene to pathological organs (in
addition to the liver, spleen). Furthermore, the physico-
chemical and biological stability issues, acid sensitivity and
bioavailability, particle size control, batch to batch reproduc-
ibility and sterilization method are still to be overcome in
order to satisfy the prerequisites of treating diseases in ani-
mals or humans.
While as novel responsive polymer compositions are
continually being developed and the ability to prepare mac-
romolecules with topological complexity is expanding, those
problems mentioned above will be solved gradually. By that
time, pH-sensitive liposomes would have been an attractive
carrier for therapeutic drugs or macromolecules with intra-
cellular targets. Furthermore, developing ‘smart’ multifunc-
tional pharmaceutical nanocarriers by combinating of pH-
sensitive liposomes with active targeting and other release
mechanisms (such as enzyme-responsive [92], temperature-
sensitive [93], light-sensitive [94], magnetic responsive [95]
and ultrasound-responsive), and selecting appropriate pH-
sensitive compositions, triggering signal and mechanism of
action to be suitable for a specific application, pH-sensitive
liposomes could be utilized in numerous medical treatments
for enhanced efficiency in the foreseeable future.r e f e r e n c e s
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